PepJunkie Home of the Peptonauts
More
HomeThe PulseAtlasDiscussHunter-GathererResearchProfileSearch

Research

Acetyl-L-Carnitine (ALCAR) — living evidence map

The Atlas page holds the claims; this is how its evidence evolved.

Summary

A meta-analysis of double-blind, placebo-controlled trials lasting 3 to 12 months in mild cognitive impairment and mild Alzheimer's disease found a small advantage for acetyl-L-carnitine over placebo on clinical and psychometric measures. · pmid:12598816

In a 24-week randomized trial in 409 women receiving taxane chemotherapy for breast cancer, acetyl-L-carnitine did not prevent neuropathy at 12 weeks and worsened it by 24 weeks compared with placebo. · pmid:23733756

Identity

PubChem CID 7045767: Acetyl-L-Carnitine, C9H17NO4, 203.24 g/mol. · pubchem:7045767

CAS registry number 3040-38-8. · pubchem:7045767

IUPAC name: (3R)-3-acetyloxy-4-(trimethylazaniumyl)butanoate. · pubchem:7045767

Where the evidence actually sits

Emerging100%

Proportion of the 2 claims about Acetyl-L-Carnitine (ALCAR) standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.

Living evidence history

Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. (2003) · emergingRandomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. (2013) · emerging20032013

2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.

Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Acetyl-L-Carnitine (ALCAR) yet.

Dose evidence, rung by rung

No established safe human dose. Nothing on file establishes one. That is a statement about the evidence PepJunkie holds, not a promise about the molecule.

  1. Approved-label dose · a resolved regulatory document names a labelled dose

    nothing resolved on this rung

  2. Studied human doses · resolved human studies at the established tier

    nothing resolved on this rung

  3. Observational evidence · resolved human data at the emerging tier: thin, or contested
    • Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. · pmid 12598816 · 2003
    • Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. · pmid 23733756 · 2013
  4. Community-reported protocols · protocol propositions from distinct members, counted once per human

    nothing resolved on this rung

  5. Preclinical evidence · resolved animal, cell or mechanistic work

    nothing resolved on this rung

2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.